The primary objective was to evaluate the durability of treatment effects through the 52-week follow-up.

Adults aged 19 and older with CRS who had failed MM elected either BSD plus MM or continued MM. Patients were evaluated at 2, 12, 24, and 52 weeks posttreatment. Balloon dilations were performed either as an office-based procedure under local anesthesia or in the operating room per physicians’ and patients’ discretion. Secondary outcomes include CSS changes, RSDI, SNOT total and subscores, sinus medication usage, missed days of work/school, the number of medical care visits, and sinus infections from baseline to the 52-week follow-up is reported here.

BSD led to sustained more significant improvements in self-reported QOL using the CSS and RSDI total scores with a trend toward improvement in the SNOT-20 total score from baseline to the 52-week follow-up compared to continued MM. There were no changes in medication usage apart from nasal steroid usage, for which the MM cohort had an increase in use. There were no device-related serious adverse events.

The results highlight the safety, effectiveness, and durability of BSD in CRS patients aged 19 and older who had previously failed MM.